The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition

Behavioural Brain Research

Volumn 143, Issue 1, 2003, Pages 7-14

  Shilling, P D ^a   Richelson, E ^b   Feifel, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Atypical antipsychotic drugs; D Amphetamine; Dizocilpine; Dopamine; Glutamate; NMDA; Schizophrenia; Typical antipsychotic drugs

Indexed keywords

DEXAMPHETAMINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR AGONIST; NT 69L; PD 149163; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG PENETRATION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT;

EID: 0037676164     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00037-8     Document Type: Article

References (46)

1. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacol. (Berl.). 122:1995;198-201.
2. Bakshi V.P., Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin an alpha-1 noradrenergic antagonist. J. Pharmacol. Exp. Ther. 283:1997;666-674.
3. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 18:1998;8394-8401.
4. Bakshi V.P., Geyer M.A. Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats. Neuroscience. 92:1999;113-121.
5. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271:1994;787-794.
6. Binder E.B., Kinkead B., Owens M.J., Kilts C.D., Nemeroff C.B. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J. Neurosci. 21:2001;601-608.
7. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol. Rev. 53:2001;453-486.
8. Boules M., Cusack B., Zhao L., Fauq A., McCormick D.J., Richelson E. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Res. 865:2000;35-44.
9. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 426:2001;73-76.
10. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry. 47:1990;181-188.
11. Chapman M.A., See R.E., Bissette G. Neurotensin increases extracellular striatal dopamine levels in vivo. Neuropeptides. 22:1992;175-183.
12. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res. 856:2000;48-54.
13. Depoortere R., Perrault G., Sanger D.J. Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav. Pharmacol. 8:1997;364-372.
14. Ervin G.N., Birkemo L.S., Nemeroff C.B., Prange A.J. Jr. Neurotensin blocks certain amphetamine-induced behaviours. Nature. 291:1981;73-76.
15. Feifel D., Minor K.L., Dulawa S., Swerdlow N.R. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 760:1997;80-84.
16. Feifel D., Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacol. (Berl.). 141:1999;93-98.
17. Feifel D., Reza T.L., Wustrow D.J., Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J. Pharmacol. Exp. Ther. 288:1999;710-713.
18. Fendt M., Schwienbacher I., Koch M. Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats. Neuroscience. 98:2000;55-60.
19. Ferraro L., Tomasini M.C., Fernandez M., Bebe B.W., O'Connor W.T., Fuxe K.et al. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. Neuroscience. 102:2001;113-120.
20. Fuxe K., Von Euler G., Agnati L.F., Merlo Pich E., O'Connor W.T., Tanganelli S.et al. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann. N.Y. Acad. Sci. 668:1992;186-204.
21. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacol. (Berl.). 156:2001;117-154.
22. Hertel P., Byskov L., Didriksen M., Arnt J. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur. J. Pharmacol. 422:2001;77-81.
23. Hokfelt T., Everitt B.J., Theodorsson-Norheim E., Goldstein M. Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp. Neurol. 222:1984;543-559.
24. Johansson C., Jackson D.M., Zhang J., Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol. Biochem. Behav. 52:1995;649-654.
25. Jolicoeur F.B., Gagne M.A., Rivest R., Drumheller A., St-Pierre S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull. 32:1993;487-491.
26. Kalivas P.W., Nemeroff C.B., Prange A.J. Jr. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience. 11:1984;919-930.
27. Kanba K.S., Kanba S., Nelson A., Okazaki H., Richelson E. [3H]neurotensin (8-13) binds in human brain to the same sites as does [3H]neurotensin but with higher affinity. J. Neurochem. 50:1988;131-137.
28. Kasckow J., Nemeroff C.B. The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. Regul. Pept. 36:1991;153-164.
29. Kinkead B., Binder E.B., Nemeroff C.B. Does neurotensin mediate the effects of antipsychotic drugs? Biol. Psychiatry. 46:1999;340-351.
30. Machida R., Tokumura T., Tsuchiya Y., Sasaki A., Abe K. Pharmacokinetics of novel hexapeptides with neurotensin activity in rats. Biol. Pharm. Bull. 16:1993;43-47.
31. Manberg P.J., Youngblood W.W., Nemeroff C.B., Rossor M.N., Iversen L.L., Prange A.J.et al. Regional distribution of neurotensin in human brain. J. Neurochem. 38:1982;1777-1780.
32. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacol. (Berl.). 94:1988;507-514.
33. Merchant K.M., Hanson G.R., Dorsa D.M. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects. J. Pharmacol. Exp. Ther. 269:1994;806-812.
34. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D.et al. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 225:1983;337-345.
35. Sanz B., Exposito I., Mora F. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport. 4:1993;1194-1196.
36. Seroogy K., Ceccatelli S., Schalling M., Hokfelt T., Frey P., Walsh J.et al. A subpopulation of dopaminergic neurons in rat ventral mesencephalon contains both neurotensin and cholecystokinin. Brain Res. 455:1988;88-98.
37. Shilling P.D., Feifel D. SR146131, a cholecystokin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI. Psychopharmacol. (Berl.). 164:2002;285-293.
38. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Rev. 31:2000;320-329.
39. Swerdlow N.R., Bakshi V., Waikar M., Taaid N., Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacol. (Berl.). 140:1998;75-80.
40. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry. 51:1994;139-154.
41. Swerdlow N.R., Geyer M.A. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol. Biochem. Behav. 44:1993;741-744.
42. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 24(2):1998;285-301.
43. Tyler-McMahon B.M., Stewart J.A., Farinas F., McCormick D.J., Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur. J. Pharmacol. 390:2000;107-111.
44. Varty G.B., Bakshi V.P., Geyer M.A. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology. 20:1999;311-321.
45. Varty G.B., Higgins G.A. Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur. J. Pharmacol. 287:1995;201-205.
46. Wustrow D.J., Davis M.D., Akunne H.C., Corbin A.E., Wiley J.N., Wise L.D.et al. Reduced amide bond neurotensin 8-13 mimetics with potent in vivo activity. Bioorg. Med. Chem. Lett. 5:1995;999-1002.